» Articles » PMID: 27761169

Characterization of the Novel Mutant A78T-HERG from a Long QT Syndrome Type 2 Patient: Instability of the Mutant Protein and Stabilization by Heat Shock Factor 1

Abstract

Background: The human ether-a-go-go-related gene (HERG) encodes the α-subunit of rapidly activating delayed-rectifier potassium channels. Mutations in this gene cause long QT syndrome type 2 (LQT2). In most cases, mutations reduce the stability of the channel protein, which can be restored by heat shock (HS).

Methods: We identified the novel mutant A78T-HERG in a patient with LQT2. The purpose of the current study was to characterize this mutant protein and test whether HS and heat shock factors (HSFs) could stabilize the mutant protein. A78T-HERG and wild-type HERG (WT-HERG) were expressed in HEK293 cells and analyzed by immunoblotting, immunoprecipitation, immunofluorescence, and whole-cell patch clamping.

Results: When expressed in HEK293 cells, WT-HERG gave rise to immature and mature forms of the protein at 135 and 155 kDa, respectively. A78T-HERG gave rise only to the immature form, which was heavily ubiquitinated. The proteasome inhibitor MG132 increased the expression of immature A78T-HERG and increased both the immature and mature forms of WT-HERG. WT-HERG, but not A78T-HERG, was expressed on the plasma membrane. In whole-cell patch clamping experiments, depolarizing pulses evoked E4031-sensitive HERG channel currents in cells transfected with WT-HERG, but not in cells transfected with A78T-HERG. The A78V mutant, but not A78G mutant, remained in the immature form similarly to A78T. Maturation of the A78T-HERG protein was facilitated by HS, expression of HSF-1, or exposure to geranyl geranyl acetone.

Conclusions: A78T-HERG was characterized by protein instability and reduced expression on the plasma membrane. The stability of the mutant was partially restored by HSF-1, indicating that HSF-1 is a target for the treatment for LQT2 caused by the A78T mutation in HERG.

Citing Articles

Multiple Dynamical Mechanisms of Phase-2 Early Afterdepolarizations in a Human Ventricular Myocyte Model: .

Kurata Y, Tsumoto K, Hayashi K, Hisatome I, Kuda Y, Tanida M Front Physiol. 2020; 10:1545.

PMID: 31998140 PMC: 6965073. DOI: 10.3389/fphys.2019.01545.


Molecular mechanisms underlying the pilsicainide-induced stabilization of hERG proteins in transfected mammalian cells.

Onohara T, Hisatome I, Kurata Y, Li P, Notsu T, Morikawa K J Arrhythm. 2017; 33(3):226-233.

PMID: 28607619 PMC: 5459418. DOI: 10.1016/j.joa.2016.09.003.

References
1.
Gong Q, Jones M, Zhou Z . Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. J Biol Chem. 2005; 281(7):4069-74. PMC: 1624912. DOI: 10.1074/jbc.M511765200. View

2.
Nakajima T, Kaneko Y, Kurabayashi M . Unveiling specific triggers and precipitating factors for fatal cardiac events in inherited arrhythmia syndromes. Circ J. 2015; 79(6):1185-92. DOI: 10.1253/circj.CJ-15-0322. View

3.
Kato M, Ogura K, Miake J, Sasaki N, Taniguchi S, Igawa O . Evidence for proteasomal degradation of Kv1.5 channel protein. Biochem Biophys Res Commun. 2005; 337(1):343-8. DOI: 10.1016/j.bbrc.2005.09.053. View

4.
Mizusawa Y, Horie M, Wilde A . Genetic and clinical advances in congenital long QT syndrome. Circ J. 2014; 78(12):2827-33. DOI: 10.1253/circj.cj-14-0905. View

5.
Anderson C, Delisle B, Anson B, Kilby J, Will M, Tester D . Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation. 2006; 113(3):365-73. DOI: 10.1161/CIRCULATIONAHA.105.570200. View